A Double-Blind Placebo-Controlled Parallel-Group Multicenter Multiregional one year Study to Assess the Efficacy and Safety of Twice daily oral Rifaximin Delayed Release Tablets for Induction of clinical Remission with Endoscopic response at 16 weeks followed by clinical and endoscopic remission at 52 weeks in Subjects with Active Moderate Crohn?s Disease
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to test if taking rifaximin can improve symptoms of active moderate Crohn's disease and maintain that improvement for the duration of study.
Description
The purpose of this study is to test if taking rifaximin can improve symptoms of active moderate Crohn's disease and maintain that improvement for the duration of study.
Details
| Condition | Crohn's disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX4994 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.